
News|Articles|November 19, 2012
Direct renin inhibitor adjunct not helpful in T2DM patients at high risk for CV, renal events
The direct renin inhibitor aliskiren, added to standard therapy with renin-angiotensin system blockade, in patients with type 2 diabetes who are at risk for cardiovascular and renal adverse events was not useful at lowering these events and may even be harmful, according to an online study published in the New England Journal of Medicine.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
4 things to know about the Abarca/LucyRx merger
2
Healthcare's AI push is creating a new workforce challenge
3
FDA expands Capvaxive indication to include adolescent patients at risk for pneumococcal disease
4
EHR-based risk calculator reduces 3-year diabetes risk in patients with prediabetes
5

































